INNOVADERM CRO IS NOW INDERO.
circle

CHORD COUSIN Collaboration (C3): Advancing Hidradenitis Suppurativa Measurement Standards

Dr. Amit Garg, MD

Dr. Amit Garg, MD

[Collaboration] Professor and founding chairman, Department of Dermatology, Zucker School of Medicine at Hofstra University

It is essential to acknowledge some of the challenges faced by investigators when evaluating disease severity in hidradenitis suppurativa (HS) trials using the currently available outcome measures. These challenges extend to rare and uncommon diseases, where the absence of robust, rigorously developed, and validated measures can deter substantial investments from companies. A notable global research organization dedicated to addressing these issues is the CHORD Cousin Collaboration (C3).

C3’s central mission revolves around the development and implementation of Core Outcome Sets (COS) for clinical trials in the realm of dermatological diseases, with the overarching goal of enhancing patient care. This initiative is not limited to HS alone but encompasses a broader spectrum of dermatological conditions, including pyoderma gangrenosum, vitiligo, eczema, and more.

Operates a consortium of over 20 COS groups, including:

  1. HOME (eczema)
  2. HiSTORIC (HS)
  3. VOICE (vitiligo)
  4. UPGRADE (pyoderma gangrenosum)
  5. COMPPASS (pustular psoriasis)

These collaborative initiatives hold the potential to revolutionize the landscape of dermatology research and drug development.

C3 HiSTORIC: Shaping the Future of HS Assessment

C3’s emphasis on HS is channeled through a group known as Hidradenitis Suppurativa Core Outcomes Set International Collaboration (HiSTORIC).

Within this group, dedicated efforts are underway to refine and develop measures that resonate with the perspectives and needs of various stakeholders, most notably, patients themselves. The goal of this initiative is to craft measures that not only encapsulate the vital aspects of HS assessment but also align with industry interests and methodological rigor.

This comprehensive approach aims to establish a COS for medical and procedural interventional trials in HS. By striving to create measures that resonate with those affected by HS, the HiSTORIC group aims to drive advancements in research and therapeutic interventions, ultimately prolonging the lives of HS patients while improving their overall quality of life.

In summary, the collaborative efforts led by organizations such as C3 and HiSTORIC highlight a fundamental shift in the approach to HS assessment. Acknowledging the need for well-defined, validated measures, these initiatives seek to renew interest and investment of improved treatments for HS and related dermatological conditions. In doing so, they offer the prospect of a brighter future for individuals dealing with the challenges of these diseases. This exemplifies the potency of collective action and collaboration in the pursuit of innovative solutions.

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.

Site Selection & Management

Our long-standing relationships with key opinion leaders and highly performing sites result in optimized start-up processes that deliver strong results in the least amount of time. As part of our site evaluation, our team utilizes past performance metrics, recruitment projections based on the competitive landscape, and detailed feasibility surveys to determine a site’s capabilities and interest in a study.

Hands, tablet and contact us with healthcare marketing or advertising on a website in the medical industry.

Patient Recruitment

Our dedicated patient recruitment and advertising team integrates with the study team to tailor recruitment strategies, customize central ad campaigns, develop advertising creative, and continuously track and adapt recruitment goals. Our patient-centric approach is enhanced by Clinago, our technology enabled recruitment service.

PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including the site selection process, budget and contract negotiations, patient engagement, and recruitment enrollment projections, all while respecting your study timelines.

PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including the site selection process, budget and contract negotiations, patient engagement, and recruitment enrollment projections, all while respecting your study timelines.